Cardio3 BioSciences (C3BS), a company working on the discovery and development of regenerative, protective and reconstructive therapies, has announced the appointment of Warren Sherman as chief medical officer, effective as of 1 November 2014. In this new role, Sherman will support the development of Cardio3 BioSciences’ product pipeline, both in cell therapies and cardiovascular diseases.
Sherman is a renowned American interventional cardiologist with more than 30 years’ experience in the field of cardiology, with a focus in cell-based therapies for treating patients post-myocardial infarction and with heart failure.
Before joining Cardio3 BioSciences as chief medical officer, Sherman was at the Columbia University Medical Center in New York, where he served in a number of capacities, including: interventional cardiologist at Columbia University Medical Center/New York-Presbyterian Hospital; director of stem cell research and regenerative medicine at the Center for Interventional Vascular Therapy; and associate professor of medicine at Columbia University College of Physicians and Surgeons.
Sherman is also the founder of the Cardiovascular Research Foundation’s International Conference on Cell Therapy for Cardiovascular Disease (IC3D), which is the foremost meeting for healthcare experts dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease. Started in 2004, this annual conference gathers leaders from the international community who present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.
Sherman received his bachelor’s degree from the Massachusetts Institute of Technology, medical degree from the State University of New York Upstate Medical School in Syracuse, and his fellowship training at Oregon Health Sciences University, in Portland, Oregon. He is certified by the American Board of Internal Medicine in Cardiology and Interventional Cardiology, and serves as an advisor to a multitude of government organisations, societies and industries.
Sherman says: “I am thrilled to be joining Cardio3 BioSciences as chief medical officer at such an exciting time in its clinical development phase. The accomplishments of this young and dynamic company are remarkable, and it is an enormous opportunity for me to be part of the most promising project in the fields of cell therapy and other treatments for cardiovascular diseases.”
Christian Homsy, chief executive officer of Cardio3 BioSciences, comments: “We are very pleased to be able to count on Warren Sherman’s expertise in clinical application, as well as his renowned scientific outreach for the further development of Cardio3 BioSciences’ future projects in regenerative therapies and cardiovascular diseases.”